Supernus Swings to Loss Amid Sage Acquisition, ZURZUVAE Launch

Ticker: SUPN · Form: 10-Q · Filed: 2025-11-06T00:00:00.000Z

Sentiment: bearish

Topics: Pharmaceuticals, Biotechnology, CNS Disorders, Acquisition, Postpartum Depression, Parkinson's Disease, Earnings Loss

Related Tickers: SUPN, BIIB

TL;DR

Supernus's Q3 loss is a tough pill to swallow, but the Sage acquisition and ZURZUVAE launch could be a long-term growth shot if they can control soaring expenses.

AI Summary

SUPERNUS PHARMACEUTICALS, INC. reported a significant net loss of $45.1 million for the three months ended September 30, 2025, a sharp decline from a net income of $38.5 million in the same period of 2024. For the nine months ended September 30, 2025, the company posted a net loss of $34.4 million, compared to a net income of $58.5 million in the prior year. Total revenues increased to $192.1 million for the three months, up from $175.7 million, primarily driven by $20.2 million in collaboration revenue from ZURZUVAE, acquired through the Sage Therapeutics acquisition on July 31, 2025. However, net product sales slightly decreased to $168.5 million from $170.3 million. Selling, general and administrative expenses surged to $179.7 million for the quarter, a 157% increase from $69.8 million in 2024, largely due to the Sage acquisition and the launch of ONAPGO in April 2025. The company also recognized a contingent consideration loss of $7.7 million for the nine months ended September 30, 2025, compared to a gain of $6.5 million in the prior year. Cash and cash equivalents significantly increased to $151.4 million as of September 30, 2025, from $69.3 million at December 31, 2024, despite the net loss, due to strategic financing and investing activities.

Why It Matters

This quarter's results are critical for investors as Supernus transitions following the major Sage Therapeutics acquisition and the launch of new products like ONAPGO and ZURZUVAE. The substantial increase in SG&A expenses reflects the integration costs and commercialization efforts, which will impact profitability in the short term. For employees, the acquisition signifies potential restructuring and new opportunities within a larger, more diversified company. Customers may benefit from expanded treatment options, particularly for postpartum depression with ZURZUVAE. In the broader market, this acquisition intensifies competition in the CNS therapeutic area, especially against other pharmaceutical companies developing treatments for depression and Parkinson's disease.

Risk Assessment

Risk Level: high — The company reported a net loss of $45.1 million for the three months ended September 30, 2025, and a net loss of $34.4 million for the nine months, a significant reversal from prior year profits. Selling, general and administrative expenses skyrocketed by 157% to $179.7 million for the quarter, indicating substantial integration and commercialization costs that are eroding profitability and increasing financial strain.

Analyst Insight

Investors should closely monitor Supernus's ability to integrate Sage Therapeutics and effectively commercialize ZURZUVAE and ONAPGO to justify the massive increase in SG&A expenses. A wait-and-see approach is advisable until there's clear evidence of revenue growth outpacing expense increases and a path back to profitability.

Financial Highlights

debt To Equity
0.35
revenue
$192.1M
operating Margin
-31.4%
total Assets
$1,419.8M
total Debt
$370.1M
net Income
-$45.1M
eps
N/A
gross Margin
89.9%
cash Position
$151.4M
revenue Growth
+8.7%

Revenue Breakdown

SegmentRevenueGrowth
Net product sales$168.5M-1.0%
Collaboration revenue (ZURZUVAE)$20.2MN/A
Royalty, licensing and other revenues$3.4M-37.0%

Key Numbers

Key Players & Entities

FAQ

What caused Supernus Pharmaceuticals' net loss in Q3 2025?

Supernus Pharmaceuticals reported a net loss of $45.1 million for the three months ended September 30, 2025, primarily due to a significant increase in selling, general and administrative expenses, which surged by 157% to $179.7 million, largely attributable to the acquisition of Sage Therapeutics and the commercial launch of ZURZUVAE and ONAPGO.

How did the Sage Therapeutics acquisition impact Supernus's financials?

The acquisition of Sage Therapeutics, completed on July 31, 2025, introduced ZURZUVAE, generating $20.2 million in collaboration revenue for the three months ended September 30, 2025. However, it also contributed significantly to the 157% increase in selling, general and administrative expenses, impacting Supernus's overall profitability.

What are the key new products for Supernus Pharmaceuticals?

Supernus Pharmaceuticals launched ONAPGO (apomorphine hydrochloride) in April 2025 for advanced Parkinson's Disease, and acquired ZURZUVAE (zuranolone) in July 2025, the first FDA-approved oral medicine for postpartum depression, through the Sage Therapeutics acquisition.

What is the strategic outlook for Supernus after the recent acquisitions and launches?

Supernus's strategic outlook is focused on leveraging its expanded neuroscience portfolio, including ZURZUVAE for postpartum depression and ONAPGO for Parkinson's Disease. The company aims to integrate Sage Therapeutics and drive commercialization efforts, despite the immediate impact on profitability from increased expenses.

What are the main risks highlighted in Supernus's 10-Q filing?

The main risks include the substantial increase in operating expenses, particularly selling, general and administrative costs, which led to a net loss of $45.1 million in Q3 2025. There's also the risk associated with integrating acquired businesses like Sage and successfully commercializing new products in competitive markets.

How did Supernus's cash position change in the first nine months of 2025?

Supernus's cash and cash equivalents significantly increased to $151.4 million as of September 30, 2025, from $69.3 million at December 31, 2024. This was primarily driven by investing activities, including maturities of marketable securities totaling $735.2 million, despite a net loss from operations.

What was the impact of the OSMOLEX ER NDA withdrawal on Supernus?

The Federal Drug Administration (FDA) withdrew the New Drug Application (NDA) for OSMOLEX ER in September 2025. While the direct financial impact isn't quantified in the summary, it indicates a setback in the company's product pipeline and potential loss of future revenue streams from that specific product candidate.

How does Supernus's current performance compare to the previous year?

For the three months ended September 30, 2025, Supernus reported a net loss of $45.1 million, a stark contrast to a net income of $38.5 million in the same period of 2024. Total revenues increased from $175.7 million to $192.1 million, but this was overshadowed by a 157% increase in selling, general and administrative expenses.

What should investors consider regarding Supernus's contingent consideration?

Investors should note that Supernus recognized a contingent consideration loss of $7.7 million for the nine months ended September 30, 2025, a significant shift from a $6.5 million gain in the prior year. This indicates potential future obligations or adjustments related to past acquisitions, which can impact earnings.

What is Supernus Pharmaceuticals' primary business focus?

Supernus Pharmaceuticals is a biopharmaceutical company primarily focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Their portfolio includes treatments for ADHD, Parkinson's Disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.

Risk Factors

Industry Context

The pharmaceutical industry is highly competitive, driven by innovation, R&D investment, and regulatory approvals. Supernus operates in a segment requiring significant capital for drug development and commercialization. Recent consolidation, like Supernus' acquisition of Sage Therapeutics, highlights a trend of companies seeking to expand pipelines and market reach through M&A.

Regulatory Implications

The pharmaceutical sector is heavily regulated by bodies like the FDA. Compliance with stringent regulations for drug development, manufacturing, and marketing is paramount. Any delays in approvals, recalls, or adverse findings can significantly impact financial performance and market access.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Collaboration revenue
Revenue generated from partnerships or agreements with other companies, often related to product development or commercialization. (Represents new income from ZURZUVAE following the Sage Therapeutics acquisition.)
Contingent consideration
An obligation to transfer additional assets or to settle a liability in the future as part of a business combination, dependent on future events. (A loss of $7.7M was recognized, impacting earnings and indicating potential future financial adjustments.)
SG&A Expenses
Selling, General, and Administrative expenses, which include costs associated with marketing, sales, management, and general operations. (These expenses surged by 157% due to acquisitions and new product launches, significantly impacting profitability.)
Intangible assets
Non-physical assets that have value, such as patents, trademarks, and goodwill, often arising from acquisitions. (Increased significantly on the balance sheet, largely due to the Sage Therapeutics acquisition.)
Goodwill
An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (Represents the premium paid in past acquisitions, with a balance of $119.1M as of September 30, 2025.)

Year-Over-Year Comparison

Total revenues for Q3 2025 increased by 8.7% to $192.1 million compared to $175.7 million in Q3 2024, primarily driven by new collaboration revenue from ZURZUVAE. However, net product sales saw a slight decrease. The most significant change is the dramatic increase in SG&A expenses, up 157% to $179.7 million, leading to a substantial swing from a net income of $38.5 million in Q3 2024 to a net loss of $45.1 million in Q3 2025. Cash position has strengthened significantly, but this is largely due to financing activities rather than operational profitability.

Filing Stats: 4,445 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2025-11-06 17:01:34

Key Financial Figures

Filing Documents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Unaudited Condensed Consolidated Financial Statements

Item 1. Unaudited Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Earnings (Loss) 4 Condensed Consolidated Statements of Comprehensive Earnings (Loss) 5 Condensed Consolidated Statements of Changes in Stockholders ' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 9

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 39

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 52

Controls and Procedures

Item 4. Controls and Procedures 52

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 53

Risk Factors

Item 1A. Risk Factors 61

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 63

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 63

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 63

Other Information

Item 5. Other Information 63

Exhibits

Item 6. Exhibits 64

SIGNATURES

SIGNATURES 66 2 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION Supernus Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (in thousands, except share data) September 30, December 31, 2025 2024 (unaudited) Assets Current assets Cash and cash equivalents $ 151,371 $ 69,331 Marketable securities 129,789 384,281 Accounts receivable, net 171,254 142,077 Inventories, net 79,399 54,293 Prepaid expenses and other current assets 62,078 36,088 Total current assets 593,891 686,070 Restricted cash 1,450 — Property and equipment, net 10,627 11,545 Intangible assets, net 623,481 521,912 Goodwill 119,080 117,019 Deferred income tax assets, net 8,793 — Other assets 62,432 31,527 Total assets $ 1,419,754 $ 1,368,073 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued liabilities $ 108,613 $ 76,352 Accrued product returns and rebates 184,459 168,705 Contingent consideration, current portion 11,235 47,340 Other current liabilities 26,322 — Total current liabilities 330,629 292,397 Contingent consideration, long-term 213 — Operating lease liabilities, long-term 31,422 27,382 Deferred income tax liabilities, net — 4,961 Other liabilities 7,823 7,600 Total liabilities 370,087 332,340 Commitments and contingencies (Note 17) Stockholders' equity Common stock, $ 0.001 par value; 130,000,000 shares authorized; 57,119,153 and 55,743,095 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 57 56 Additional paid-in capital 527,700 479,440 Accumulated other comprehensive loss, net of tax ( 71 ) ( 189 ) Retained earnings 521,981 556,426 Total stockholders' equity 1,049,667 1,035,733 Total liabilities and stockholders' equity $ 1,419,754 $ 1,368,073 See accompanying notes. 3 Table of Contents Supernus Pharmaceuticals, Inc. Condensed Consolidated Statements of Earnings (Loss) (in thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2025

View on Read The Filing